跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
吳 美儀
教授
,
腎臟內科
合聘教授
,
臨床基因體學暨蛋白質體學碩士學位學程
主治醫師
,
衛生福利部雙和醫院
成員
,
臺北醫學大學泌尿腎臟研究中心
成員
,
臺北醫學大學器官移植研究中心
https://orcid.org/0000-0002-5777-2752
電子郵件
e220121
gmail
com
h-index
2058
引文
28
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2007
2026
每年研究成果
概覽
指紋
網路
專案
(16)
研究成果
(112)
資料集
(6)
類似的個人檔案
(12)
指紋
查看啟用 Mei-Yi Wu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
4 Iodo 2,5 Dimethoxyamphetamine
8%
Acute Kidney Injury
7%
Adverse Event
6%
All Cause Mortality
15%
Apoplexy
6%
Carbon Monoxide Intoxication
8%
Cardiovascular Disease
28%
Chronic Kidney Disease
86%
Cohort Analysis
35%
Computer Assisted Tomography
5%
Congestive Heart Failure
9%
Contrast Medium
5%
Contrast-Induced Nephropathy
8%
Deterioration
9%
Diabetes
6%
Diabetes Mellitus
7%
Diseases
5%
Division
8%
Education
5%
End Stage Renal Disease
30%
Focal Segmental Glomerulosclerosis
5%
Hazard Ratio
15%
Hemodialysis
17%
Home Hemodialysis
8%
Intensive Care Unit
5%
Internal Medicine
8%
Kidney Function
24%
Kidney Graft
9%
Kidney Injury
5%
Kidney Transplantation
14%
Meta-Analysis
44%
Metabolic Syndrome
6%
Nephrology
10%
Nephropathy
22%
Nocturia
8%
Observational Study
7%
Odds Ratio
5%
Oral
9%
Patient Care
6%
Peritoneal Dialysis
8%
Prevalence
7%
Proportional Hazards Model
6%
Randomized Controlled Trial
21%
Renal Replacement Therapy
6%
Retrospective Cohort Study
6%
Sepsis
9%
Systematic Review
37%
Therapy Effect
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
6%
Adverse Effect
5%
Adverse Event
13%
Albumin
5%
All Cause Mortality
12%
Angiotensin Receptor Antagonist
8%
Carbon Monoxide Poisoning
13%
Cardiovascular Disease
17%
Chronic Kidney Failure
100%
Cohort Study
21%
Deterioration
13%
Dipeptidyl Carboxypeptidase Inhibitor
8%
Diseases
5%
End Stage Renal Disease
22%
Fibrosis
5%
Fucoidan
5%
Gentamicin
8%
Glucose
7%
Hemodialysis
19%
Hypertension
7%
Hyperuricemia
6%
Infection
5%
Inflammation
7%
Influenza
8%
Monotherapy
10%
Observational Study
6%
Omega-3 Fatty Acid
8%
Peritoneal Fibrosis
8%
Placebo
13%
Random Effects Model
5%
Randomized Controlled Trial
25%
Replacement Therapy
12%
Therapeutic Effect
5%
Tuberculosis
8%
Vaccination
13%
Nursing and Health Professions
Acute Kidney Failure
8%
All Cause Mortality
10%
Blood Pressure
5%
Body Mass
8%
Cardiovascular Disease
16%
Cerebrovascular Accident
5%
Chronic Kidney Failure
64%
Cohort Analysis
19%
Confidence Interval
14%
Congestive Heart Failure
9%
Deterioration
9%
Education
5%
Efficacy
5%
End Stage Renal Disease
16%
Hazard Ratio
7%
Hemodialysis
8%
Hypertension
5%
Kidney Disease
8%
Meta Analysis
30%
National Health Insurance
6%
Odds Ratio
5%
Organ Transplantation
6%
Practice Guideline
5%
Prevalence
8%
Proportional Hazards Model
6%
School Health Service
8%
Sepsis
13%
Systematic Review
24%
Tuberculosis
13%
